How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-09
DOI
10.1007/s40273-021-01065-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA Approval and Regulation of Pharmaceuticals, 1983-2018
- (2020) Jonathan J. Darrow et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
- (2020) Olivier J. Wouters et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices
- (2020) Brendan Shaw et al. PHARMACOECONOMICS
- Pricing and Paying for Cancer Drugs
- (2020) David A. Hyman et al. CANCER JOURNAL
- Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US
- (2020) Sebastian Salas-Vega et al. SOCIAL SCIENCE & MEDICINE
- Estimating the clinical cost of drug development for orphan versus non-orphan drugs
- (2019) Kavisha Jayasundara et al. Orphanet Journal of Rare Diseases
- An analysis of orphan medicine expenditure in Europe: is it sustainable?
- (2019) Jorge Mestre-Ferrandiz et al. Orphanet Journal of Rare Diseases
- Outrageous prices of orphan drugs: a call for collaboration
- (2018) Lucio Luzzatto et al. LANCET
- Sustainability and affordability of cancer drugs: a novel pricing model
- (2018) Carin A. Uyl-de Groot et al. Nature Reviews Clinical Oncology
- Assessing Pharmaceutical Research and Development Costs
- (2018) Joseph A. DiMasi JAMA Internal Medicine
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- Drug development in the era of precision medicine
- (2017) Sarah A. Dugger et al. NATURE REVIEWS DRUG DISCOVERY
- A Much-Needed Corrective on Drug Development Costs
- (2017) Merrill Goozner JAMA Internal Medicine
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
- (2017) Vinay Prasad et al. JAMA Internal Medicine
- The High Cost of Prescription Drugs in the United States
- (2016) Aaron S. Kesselheim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Innovation in the pharmaceutical industry: New estimates of R&D costs
- (2016) Joseph A. DiMasi et al. JOURNAL OF HEALTH ECONOMICS
- Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
- (2016) Sabine Vogler et al. LANCET ONCOLOGY
- Actual costs of cancer drugs in 15 European countries
- (2016) Wim H van Harten et al. LANCET ONCOLOGY
- Early market access of cancer drugs in the EU
- (2015) J. Martinalbo et al. ANNALS OF ONCOLOGY
- Improving R&D productivity
- (2015) Katarzyna Smietana et al. NATURE REVIEWS DRUG DISCOVERY
- The $2.6 Billion Pill — Methodologic and Policy Considerations
- (2015) Jerry Avorn NEW ENGLAND JOURNAL OF MEDICINE
- The Cost of Drug Development
- (2015) Joseph A. DiMasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accelerated Access to Innovative Medicines for Patients in Need
- (2014) L G Baird et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer
- (2014) Adam Falconi et al. Journal of Thoracic Oncology
- Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
- (2014) Michael Schlander et al. Journal of Comparative Effectiveness Research
- AN INSTRUMENT FOR MEASURING THE SOCIAL WILLINGNESS TO PAY FOR HEALTH STATE IMPROVEMENT
- (2013) Jeff Richardson et al. HEALTH ECONOMICS
- Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines
- (2013) Ayman Chit et al. VACCINE
- Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
- (2012) H-G Eichler et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cost-Effectiveness Assessment of Orphan Drugs
- (2012) Steven Simoens et al. Applied Health Economics and Health Policy
- The cost of drug development: A systematic review
- (2011) Steve Morgan et al. HEALTH POLICY
- The productivity crisis in pharmaceutical R&D
- (2011) Fabio Pammolli et al. NATURE REVIEWS DRUG DISCOVERY
- Pricing and reimbursement of orphan drugs: the need for more transparency
- (2011) Steven Simoens Orphanet Journal of Rare Diseases
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
- (2010) J A DiMasi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A flexible blueprint for the future of drug development
- (2010) Richard Barker LANCET
- How to improve R&D productivity: the pharmaceutical industry's grand challenge
- (2010) Steven M. Paul et al. NATURE REVIEWS DRUG DISCOVERY
- Spending on new drug development
- (2009) Christopher Paul Adams et al. HEALTH ECONOMICS
- Misleading Congress about Drug Development: Reply
- (2008) Joseph A. DiMasi et al. JOURNAL OF HEALTH POLITICS POLICY AND LAW
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation